Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06712810
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:11.888941+00:00
Published At
2025-10-10T00:00:00+00:00
Record Updated At
2025-10-10
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Hematopoietic and Lymphatic System Neoplasm", "Histiocytic Sarcoma", "Malignant Histiocytosis", "Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Follicular Lymphoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Lymphoplasmacytic Lymphoma", "Recurrent Myelodysplastic Syndrome", "Recurrent Myelofibrosis", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Waldenstrom Macroglobulinemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Erdheim-Chester Disease", "Refractory Follicular Lymphoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Lymphoplasmacytic Lymphoma", "Refractory Myelodysplastic Syndrome", "Refractory Myelofibrosis", "Refractory Small Lymphocytic Lymphoma", "Refractory Waldenstrom Macroglobulinemia", "Rosai-Dorfman-Destombes Disease", "Primary Central Nervous System Lymphoma", "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm", "Recurrent Erdheim-Chester Disease", "Recurrent Fibroblastic Reticular Cell Sarcoma", "Recurrent Histiocytic Sarcoma", "Recurrent Interdigitating Dendritic Cell Sarcoma", "Recurrent Rosai-Dorfman-Destombes Disease", "Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm", "Refractory Fibroblastic Reticular Cell Sarcoma", "Refractory Histiocytic Sarcoma", "Refractory Interdigitating Dendritic Cell Sarcoma", "Refractory Rosai-Dorfman-Destombes Disease"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-10-10"
protocolSection.identificationModule.nctId
"NCT06712810"
protocolSection.identificationModule.officialTitle
"MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Hematopoietic and Lymphatic System Neoplasm (protocolSection.conditionsModule.conditions)
  • Histiocytic Sarcoma (protocolSection.conditionsModule.conditions)
  • Malignant Histiocytosis (protocolSection.conditionsModule.conditions)
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
  • Primary Cutaneous T-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Langerhans Cell Histiocytosis (protocolSection.conditionsModule.conditions)
  • Recurrent Lymphoplasmacytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Recurrent Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Recurrent Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Waldenstrom Macroglobulinemia (protocolSection.conditionsModule.conditions)
  • Refractory Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Erdheim-Chester Disease (protocolSection.conditionsModule.conditions)
  • Refractory Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Langerhans Cell Histiocytosis (protocolSection.conditionsModule.conditions)
  • Refractory Lymphoplasmacytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Refractory Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Refractory Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Waldenstrom Macroglobulinemia (protocolSection.conditionsModule.conditions)
  • Rosai-Dorfman-Destombes Disease (protocolSection.conditionsModule.conditions)
  • Primary Central Nervous System Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Erdheim-Chester Disease (protocolSection.conditionsModule.conditions)
  • Recurrent Fibroblastic Reticular Cell Sarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Histiocytic Sarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Interdigitating Dendritic Cell Sarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Rosai-Dorfman-Destombes Disease (protocolSection.conditionsModule.conditions)
  • Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (protocolSection.conditionsModule.conditions)
  • Refractory Fibroblastic Reticular Cell Sarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Histiocytic Sarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Interdigitating Dendritic Cell Sarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Rosai-Dorfman-Destombes Disease (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.